EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From albuminuria to multi-omics signatures: emerging biomarkers and drug targets for early-stage chronic kidney disease

Kaili Chen, Yadong Zheng, Siyu Huang, Linqi Zhang

Frontiers in Pharmacology · 09.04.2026 · 17

DOI: 10.3389/fphar.2026.1765974 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.04.2026. Verfasst von Kaili Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephropathy, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is highly prevalent worldwide, yet structural kidney injury often develops long before changes in estimated glomerular filtration rate (eGFR) or persistent albuminuria are detected. Albuminuria is a well-established prognostic marker and treatment target, but it captures only part of the biological diversity of early kidney damage, shows substantial within-person variability, and may miss risk in predominantly tubulointerstitial or microvascular forms of disease. Recent advances in high-throughput omics now allow detailed profiling of renal stress in urine, blood and tissue, yielding proteomic, metabolomic, transcriptomic, epigenetic and non-coding RNA signatures linked to tubular injury, inflammation, fibrosis, mitochondrial dysfunction and disturbed energy metabolism. When these molecular layers are analysed in combination, multi-omics signatures can improve risk stratification beyond conventional Kidney Disease: Improving Global Outcomes (KDIGO) staging, help to define mechanistically distinct patient subgroups and highlight candidate therapeutic targets in haemodynamic–metabolic, immune/complement and extracellular matrix pathways. In this mini-review, we summarise the emerging evidence supporting a move beyond an albuminuria-centred view of early CKD towards mechanistically informed, multi-omics-based biomarkers, and we outline key requirements for clinical translation, including analytical standardisation, longitudinal validation and proof that such markers deliver actionable gains in patient care.

Schlagwörter

Stichwörter der Autor:innen

albuminuriabiomarkerschronic kidney diseaseearly-stage CKDmulti-omicsurinary proteomics

Autor:innen und Institutionen

  • Department of Nephropathy, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
  • First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, China.
  • Institute of Rehabilitation Medicine, Henan Academy of Innovations in Medical Science, Zhengzhou, China.

Zitieren

APA

Chen, K., Zheng, Y., Huang, S., & Zhang, L. (2026). From albuminuria to multi-omics signatures: emerging biomarkers and drug targets for early-stage chronic kidney disease. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1765974

Vancouver

Chen K, Zheng Y, Huang S, Zhang L. From albuminuria to multi-omics signatures: emerging biomarkers and drug targets for early-stage chronic kidney disease. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1765974

BibTeX
@article{Chen2026,
  author = {Chen, Kaili and Zheng, Yadong and Huang, Siyu and Zhang, Linqi},
  title = {From albuminuria to multi-omics signatures: emerging biomarkers and drug targets for early-stage chronic kidney disease},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1765974}
}
Kostenlos starten →